Numerous clinical trials have investigated the therapeutic potential of combining BTK inhibitors with other drugs for CNS lymphoma treatment, including chemotherapy agents, immune checkpoint inhibitors, PI3K/AKT/mTOR inhibitors, immunomodulatory imide drugs, and various multi‐agent combinations.16, 33. This evidence concerns the gene MTOR and primary central nervous system lymphoma.